Group 1 - The company Fonda Holdings (01521) has entered into a share transfer agreement to acquire Shanghai Guanhua Medical Technology Co., Ltd. for a total consideration of RMB 270 million, which will make the target company a wholly-owned subsidiary after completion [1][2] - The acquisition aims to enhance the group's global laboratory service capabilities and strengthen its influence in China, as the target group is a leading provider of clinical research laboratory services with extensive experience in supporting over 1,500 clinical trials [2] - The target company's successful track record includes contributions to the successful launch of 35 new drugs and support for regulatory audits, which aligns well with the group's existing expertise [2] Group 2 - The target company primarily engages in clinical trial technology services, related services, and laboratory services, with its wholly-owned subsidiaries focusing on clinical research services [2] - Following the acquisition, the group's financial performance will be consolidated into its financial statements, and the registered capital of the target company will be reduced to RMB 45,169,326 after the buyback and capital reduction [1] - The acquisition is expected to be completed by October 31, 2025, and will further solidify the group's position as a trusted partner in the clinical research industry by enhancing its ability to provide high-quality one-stop services to pharmaceutical companies and research institutions [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 FRONTAGE HOLDINGS CORPORATION 方達控股公司* （於開曼群島註冊成立的有限公司） （股份代號：1521） 有關收購目標公司全部已發行股本的 重大及關連交易 上市規則之涵義 由於收購事項之最高適用百分比率（定義見上市規則）高於25%但低於100%，故 收購事項構成本公司之主要交易，因此須遵守上市規則第十四章項下的申報、 公告、通函及股東批准規定。 1 截至本公告日期，杭州泰格為本公司的控股股東，通過香港泰格直接及間接持 有合共佔已發行股份總數約64.57%。因此，杭州泰格及嘉興欣格均為本公司之 關連人士，而根據上市規則第十四A章，收購事項構成本公司之關連交易。鑒於 收購事項之最高適用百分比率（定義見上市規則）超過5%，收購事項須遵守上市 規則第十四A章項下的申報、公告、通函及獨立股東批准規定。 獨立董事委員會及獨立財務顧問 本公司已成立由全體獨立非執行董事組成的獨立董事委員會， ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 方達控股公司 (於開曼群島註冊成立的有限公司) 呈交日期: 2025年10月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01521 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 5 ...

Core Insights - Fonda Holdings and GCCL signed a strategic memorandum of understanding (MOU) to enhance their influence in the global clinical trial market [1][3] - The collaboration aims to leverage both companies' service and laboratory network advantages to improve competitiveness in the US and Asia-Pacific regions [1][3] Company Overview - GCCL is a leading clinical trial sample analysis provider in South Korea, offering integrated "one-stop solutions" including central laboratories and bioanalytical laboratories [4] - Fonda Holdings is a comprehensive pharmaceutical R&D CRO with established centers in China, North America, and Europe, providing a wide range of outsourced R&D services [5] Strategic Collaboration - The partnership will explore joint clinical trial services, co-marketing, project support plans, and the development of new business opportunities [3] - Both companies will combine their regional expertise and global networks to execute clinical trial projects more efficiently and effectively [3] Leadership Statements - Fonda Holdings' Senior Vice President, Dr. Zhang Nan, emphasized the importance of this strategic cooperation in enhancing their influence in the Asia-Pacific market and providing faster, more efficient support for global clinical trials [3] - GCCL's CEO, KwanGoo Cho, highlighted the goal of creating new growth opportunities in the global clinical trial market by combining GCCL's strengths in bioanalysis and central laboratory services with Fonda's global capabilities [3]

23 September 2025 Frontage Holdings Corporation (the "Company") – Notice of publication of 2025 Interim Report (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's website at www.frontagelab.com and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at www.hkexnews.hk respectively (the "Website Version"). The Company strongly recommends you to access the Website Version of Current ...

FRONTAGE HOLDINGS CORPORATION 方達控股公司* (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） （Stock Code 股份代號：1521） NOTIFICATION LETTER 通知信函 Dear Registered Shareholders, 23 September 2025 Frontage Holdings Corporation (the "Company") – Notice of publication of 2025 Interim Report (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are now available on the Company's website at www.frontagelab.com and the website of ...

FRONTAGE HOLDINGS CORPORATION 方達控股公司* (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） （Stock Code 股份代號：1521） NOTIFICATION LETTER 通知信函 Dear Non-Registered Shareholders, 23 September 2024 Frontage Holdings Corporation (the "Company") – Notice of publication of 2024 Interim Report (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's website at www.frontagelab.com and the website of ...

FRONTAGE HOLDINGS CORPORATION 方達控股公司* (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） （Stock Code 股份代號：1521） NOTIFICATION LETTER 通知信函 Dear Registered Shareholders, 23 September 2024 Frontage Holdings Corporation (the "Company") – Notice of publication of 2024 Interim Report (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are now available on the Company's website at www.frontagelab.com and the website of ...

Frontage Holdings Corporation 方達控股公司 * 股份代號 : 1521 （於開曼群島註冊成立的有限公司） 2025 中期報告 * 僅供識別 | 公司資料 | 2 | | --- | --- | | 財務摘要 | 3 | | 管理層討論及分析 | 5 | | 企業管治及其他資料 | 27 | | 簡明綜合財務報表審閱報告 | 49 | | 簡明綜合損益及其他全面收益表 | 51 | | 簡明綜合財務狀況表 | 52 | | 簡明綜合權益變動表 | 54 | | 簡明綜合現金流量表 | 56 | | 簡明綜合財務報表附註 | 57 | | 釋義 | 96 | 公司資料 董事會 執行董事 李松博士 （主席） Wentao Zhang博士（於2025年1月6日 獲委任為聯席行政總裁，並於2025年 5月28日獲委任為執行董事） Zhongping Lin博士（於2025年1月6日 獲委任為聯席行政總裁，並於2025年 5月28日獲委任為執行董事） 非執行董事 李志和博士（於2025年5月28日辭任） Zhuan Yin女士 吳灝先生 獨立非執行董事 李軼梵先生 劉二飛先生 王勁松博士 審 ...

Core Viewpoint - Fangda Holdings (01521) experienced a nearly 10% increase in stock price, reaching HKD 1.45, with a trading volume of HKD 1.925 million, following the release of its financial results for the six months ending June 30, 2025 [1] Financial Performance - The company reported revenues of USD 127 million for the period, reflecting a year-on-year decrease of 1.5% [1] - The profit attributable to shareholders was USD 2.927 million, marking a turnaround from a loss in the previous year [1] - Basic earnings per share were USD 0.0014 [1] Quarterly Breakdown - In the first quarter of 2025, the company recorded a loss; however, the financial performance improved in the second quarter due to increased market demand and biopharmaceutical companies outsourcing to reduce costs [1] - The second quarter revenues were approximately USD 69.5 million, representing a year-on-year increase of 7.8%, with a net profit of around USD 3.8 million [1]